CD33 and acute myeloid leukemia: Despite the relative appeal of CD33 as an AML tumor-associated antigen (TAA), therapeutics targeting CD33 have substantial clinical toxicity, presumably caused at least in part by expression on healthy myeloid cells (9–11).